CollPlant Biotechnologies (CLGN) Total Liabilities (2017 - 2025)
CollPlant Biotechnologies' (CLGN) quarterly Total Liabilities came in at $4.7 million in Q4 2025, down 10.31% YoY from $5.2 million in Q4 2024, and down 1.67% on a QoQ basis from $4.8 million in Q3 2025.
CollPlant Biotechnologies (CLGN) Total Liabilities (2017 - 2025) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 9 years of Total Liabilities data on file, last reported at $4.7 million in Q4 2025.
- Quarterly Total Liabilities fell 10.31% year-over-year to $4.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.7 million (down 10.31% YoY) and the FY2025 annual result came in at $4.7 million, down 10.31% from the prior year.
- Total Liabilities declined to $4.7 million in Q4 2025, from $4.8 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $6.1 million in Q4 2021 to a low of $4.7 million in Q4 2025.
- A 5-year average of $5.4 million and a median of $5.5 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2023 — Total Liabilities advanced 12.67% — and 2025, when it fell 15.5%.
- Tracing CLGN's Total Liabilities over 5 years: stood at $6.1 million in 2021, then fell by 10.09% to $5.5 million in 2022, then climbed by 5.45% to $5.8 million in 2023, then dropped by 9.35% to $5.2 million in 2024, then dropped by 10.31% to $4.7 million in 2025.
- The last three Total Liabilities figures came in at $4.7 million (Q4 2025), $4.8 million (Q3 2025), and $4.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | CollPlant Biotechnologies | 4.13 Mn | 4.13 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.70 Mn |
| Sep 30, 2025 | 4.78 Mn |
| Jun 30, 2025 | 4.93 Mn |
| Dec 31, 2024 | 5.25 Mn |
| Sep 30, 2024 | 5.52 Mn |
| Jun 30, 2024 | 5.84 Mn |
| Mar 31, 2024 | 5.85 Mn |
| Dec 31, 2023 | 5.79 Mn |
| Sep 30, 2023 | 5.16 Mn |
| Jun 30, 2023 | 5.53 Mn |
| Mar 31, 2023 | 5.87 Mn |
| Dec 31, 2022 | 5.49 Mn |
| Sep 30, 2022 | 4.75 Mn |
| Jun 30, 2022 | 4.91 Mn |
| Mar 31, 2022 | 5.53 Mn |
| Dec 31, 2021 | 6.10 Mn |
| Sep 30, 2021 | 5.15 Mn |
| Jun 30, 2021 | 5.58 Mn |
| Mar 31, 2021 | 5.99 Mn |
| Dec 31, 2020 | 6.36 Mn |